UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
SCHEDULE 13D*
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Myrexis, Inc.
- -------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.01 per share
- -------------------------------------------------------------------------------
(Title of Class of Securities)
62856H107
- -------------------------------------------------------------------------------
(CUSIP Number)
Mark Goldstein
First Eagle Investment Management, LLC
1345 Avenue of the Americas
New York, New York 10105
(212) 698-3101
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 1, 2010
- -------------------------------------------------------------------------------
(Date of Event which Requires
Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box. [ ]
NOTE: Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 6 Pages)
- --------------------------
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
- ------------------------- --------------------
CUSIP NO. 62856H107 SCHEDULE 13D/A PAGE 2 OF 6 PAGES
- ------------------------- --------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
First Eagle Investment Management, LLC
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [x]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
2,741,604
---------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 2,741,604
---------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
2,741,604
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.85%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IA
- -------------------------------------------------------------------------------
- ------------------------- --------------------
CUSIP NO. 62856H107 SCHEDULE 13D/A PAGE 3 OF 6 PAGES
- ------------------------- --------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
First Eagle Value in Biotechnology Master Fund Ltd.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
---------------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 1,729,434
OWNED BY ---------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH -0-
---------------------------------------------------------
10 SHARED DISPOSITIVE POWER
1,729,434
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
1,729,434
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.85%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
- ------------------------- --------------------
CUSIP NO. 62856H107 SCHEDULE 13D/A PAGE 4 OF 6 PAGES
- ------------------------- --------------------
ITEM 1. SECURITY AND ISSUER.
This constitutes Amendment No. 2 (this "Amendment") to the Schedule 13D
previously filed by the Reporting Persons on December 24, 2009 and amended
on September 30, 2010 (collectively the "Original Schedule 13D") with
respect to shares of common stock, $.01 par value per share (the "Shares"),
of Myrexis, Inc. (the "Issuer"). Capitalized terms used herein and not
otherwise defined in this Amendment have the meanings set forth in
the Original Schedule 13D. This Amendment amends Item 5 as set
forth below.
ITEM 5. INTEREST IN SECURITIES OF THE COMPANY.
(a) As of the close of business on December 2, 2010, (i) FEIM is deemed
to be the beneficial owner of 2,741,604 Shares, constituting approximately
10.85% of the Shares outstanding (which includes the Shares as to which
FEVIB may be deemed to be the beneficial owner) and (ii) FEVIB is deemed
to be the beneficial owner of 1,729,434 Shares, constituting approximately
6.85% of the Shares outstanding. The aggregate percentage of Shares
reported herein is based upon 25,260,397 Shares outstanding, which is the
total number of Shares outstanding as of November 3, 2010 as reported in
the Issuer's Annual Report on Form 10-Q filed on November 9, 2010 for the
quarterly period ended September 30, 2010.
(b) By virtue of investment management agreements with its clients, including
with FEVIB, FEIM shares with such clients voting and dispositive powers
over the 2,741,604 Shares reported herein, which powers are exercised by
the Principal and the Portfolio Managers.
(c) Information concerning transactions in the Shares effected by the
Reporting Persons during the past sixty days is set forth in Schedule A
hereto and is incorporated herein by reference. Except as otherwise
indicated, all of the transactions in Shares listed on Schedule A
hereto were effected in the open market.
(d) Clients of FEIM, including FEVIB, have the right to receive and the
ultimate power to direct the receipt of dividends from, or the proceeds
of the sale of, the Shares reported herein.
(e) Not applicable.
- ------------------------- --------------------
CUSIP NO. 62856H107 SCHEDULE 13D/A PAGE 5 OF 6 PAGES
- ------------------------- --------------------
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the
undersigned certifies that the information set forth in this statement is true,
complete and correct.
Dated: December 2, 2010
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
By: /s/ Mark Goldstein
----------------------
Name: Mark Goldstein
Title: Senior Vice President
FIRST EAGLE VALUE IN BIOTECHNOLOGY MASTER
FUND LTD.
By: FIRST EAGLE INVESTMENT MANAGEMENT, LLC,
Its Investment Manager
By: /s/ Mark Goldstein
----------------------
Name: Mark Goldstein
Title: Senior Vice President
- ------------------------- --------------------
CUSIP NO. 62856H107 SCHEDULE 13D/A PAGE 6 OF 6 PAGES
- ------------------------- --------------------
SCHEDULE A
TRANSACTIONS IN THE SHARES BY THE REPORTING PERSON DURING THE PAST 60 DAYS
Unless otherwise indicated, all trades were effected in the open market through
brokers.
Date of Transaction Shares Purchased (Sold) Price Per Share ($)*
- ------------------- ----------------------- -------------------
10/04/10 5,505 3.75
11/10/10 ** 14,494 3.61
11/10/10 14,493 3.61
11/11/10 ** 18,950 3.62
11/11/10 18,950 3.62
11/12/10 ** 3,450 3.62
11/12/10 3,450 3.62
11/23/10 ** 4,037 3.66
11/23/10 4,037 3.66
11/24/10 ** 9,303 3.70
11/24/10 9,303 3.70
11/26/10 ** 69,752 3.70
11/26/10 69,751 3.70
12/01/10 ** 4,852 3.70
12/01/10 4,852 3.70
12/02/10 ** 50 3.69
12/02/10 50 3.69
* Excluding commissions.
** Trade effected by FEVIB